Australia's most trusted
source of pharma news
Tuesday, 13 May 2025
Posted 12 May 2025 AM
Taiho Pharma’s Lytgobi and Specialised Therapeutics’ Yorvipath are among 11 additions to the PBAC’s July agenda, stretching the total number of items under consideration to almost 60.
Both newcomers were knocked back at the committee’s March 2025 meeting with Lytgobi offered the early re-entry pathway.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.